Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001737287-25-000024
Filing Date
2025-03-04
Accepted
2025-03-04 21:58:30
Documents
3
Period of Report
2025-03-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1741143503.html 3  
1 FORM 3 wk-form3_1741143503.xml 3 7180
2 EX-24 bbeneski_section16powero.htm EX-24 3849
3 GRAPHIC bbeneski_section16powero001.jpg GRAPHIC 218940
  Complete submission text file 0001737287-25-000024.txt   314094
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Beneski Benjamin Machinas (Reporting) CIK: 0002057918 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38693 | Film No.: 25708570